» Articles » PMID: 36921180

A Case-control Study of Clostridioides Difficile Symptomatic Infections in a Pediatric Cancer Hospital

Abstract

Objective: The aim of this study was to analyze and identify documented infections and possible risk factors for Clostridioides difficile infections in children with cancer.

Methods: This is a retrospective case-control study, carried out in a pediatric cancer hospital, covering the years 2016-2019. Matching was performed by age and underlying disease, and for each case, the number of controls varied from 1 to 3. Logistic regression models were used to assess risk factors.

Results: We analyzed 63 cases of documented infection by C. difficile and 125 controls. Diarrhea was present in all cases, accompanied by fever higher than 38°C in 52.4% of the patients. Mortality was similar among cases (n=4; 6.3%) and controls (n=6; 4.8%; p=0.7). In all, 71% of patients in the case group and 53% in the control group received broad-spectrum antibiotics prior to the infection. For previous use of vancomycin, the Odds Ratio for C. difficile infection was 5.4 (95% confidence interval [95%CI] 2.3-12.5); for meropenem, 4.41 (95%CI 2.1-9.2); and for cefepime, 2.6 (95%CI 1.3-5.1). For the antineoplastic agents, the Odds Ratio for carboplatin was 2.7 (95%CI 1.2-6.2), melphalan 9.04 (95%CI 1.9-42.3), busulfan 16.7 (95%CI 2.1-134.9), and asparaginase 8.97 (95%CI 1.9-42.9).

Conclusions: C. difficile symptomatic infection in children with cancer was associated with previous hospitalization and the use of common antibiotics in cancer patients, such as vancomycin, meropenem, and cefepime, in the last 3 months. Chemotherapy drugs, such as carboplatin, melphalan, busulfan, and asparaginase, were also risk factors.

References
1.
Brown K, Khanafer N, Daneman N, Fisman D . Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013; 57(5):2326-32. PMC: 3632900. DOI: 10.1128/AAC.02176-12. View

2.
Kim J . Editorial commentary: Clostridium difficile in pediatric oncology patients: more questions than answers. Clin Infect Dis. 2014; 59(3):404-5. DOI: 10.1093/cid/ciu308. View

3.
Chopra T, Chandrasekar P, Salimnia H, Heilbrun L, Smith D, Alangaden G . Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant. 2010; 25(1):E82-7. PMC: 3860287. DOI: 10.1111/j.1399-0012.2010.01331.x. View

4.
Dominguez S, Dolan S, West K, Dantes R, Epson E, Friedman D . High colonization rate and prolonged shedding of Clostridium difficile in pediatric oncology patients. Clin Infect Dis. 2014; 59(3):401-3. PMC: 9632259. DOI: 10.1093/cid/ciu302. View

5.
de Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R . Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr. 2013; 163(3):699-705.e1. PMC: 4550005. DOI: 10.1016/j.jpeds.2013.01.062. View